Dieter Naber

Universität Hamburg — Germany

Medicine · Health Sciences

64h-index15.1kcitations579works4.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Schizophrenia research and treatment(329), Mental Health and Psychiatry(132), Bipolar Disorder and Treatment(76), Treatment of Major Depression(75), Psychiatric care and mental health services(73)

Publications579 total

Autorinnen und Autoren
Elsevier eBooks·2025
Pharmakotherapie der Schizophrenie (ICD-10 F2)
Elsevier eBooks·2025
Relapse in Schizophrenia: A Systematic Review of Criteria for Clinical Studies and International Consensus Guidelines to Improve Them
American Journal of Psychiatry·2025· 3 cited
Efficacy of clozapine versus second-generation antipsychotics in people with treatment-resistant schizophrenia: a systematic review and individual patient data meta-analysis
The Lancet Psychiatry·2025· 20 citedOpen Access
Pharmakotherapie der Schizophrenie (ICD-10 F2)
Elsevier eBooks·2024· 1 cited
Autorinnen und Autoren
Elsevier eBooks·2024Open Access
Clozapine Optimization: A Delphi Consensus Guideline From the Treatment Response and Resistance in Psychosis Working Group
Schizophrenia Bulletin·2023· 35 citedOpen Access
Personal and Social Functioning and Health-Related Quality of Life in Patients with Schizophrenia Treated with the Long-Acting Injectable Antipsychotic Risperidone ISM
Neuropsychiatric Disease and Treatment·2023· 9 citedOpen Access
Changing the Antipsychotic in Early Nonimprovers to Amisulpride or Olanzapine: Randomized, Double-Blind Trial in Patients With Schizophrenia
Schizophrenia Bulletin·2022· 12 citedOpen Access
Corrigendum to “Long-term efficacy and safety of once-monthly Risperidone ISM® in the treatment of schizophrenia: Results from a 12-month open-label extension study” [Schizophr. Res. 239 (2022) 83–91]
Schizophrenia Research·2022
P.0839 Risperidone ISM® effect size evaluation: post-hoc findings from the prisma-3 phase III study
European Neuropsychopharmacology·2021· 2 cited
Long-term efficacy and safety of once-monthly Risperidone ISM® in the treatment of schizophrenia: Results from a 12-month open-label extension study
Schizophrenia Research·2021· 19 citedOpen Access
Efficacy and safety of once-monthly Risperidone ISM® in schizophrenic patients with an acute exacerbation
Schizophrenia·2020· 35 citedOpen Access
What happens with schizophrenia patients after their discharge from hospital? Results on outcome and treatment from a “real-world” 2-year follow-up trial
European Archives of Psychiatry and Clinical Neuroscience·2019· 10 cited
Remission in schizophrenia — What are we measuring? Comparing the consensus remission criteria to a CGI-based definition of remission and to remission in major depression
Schizophrenia Research·2019· 12 cited
Disparate effects of first and second generation antipsychotics on cognition in schizophrenia – Findings from the randomized NeSSy trial
European Neuropsychopharmacology·2019· 35 cited
Autorinnen und Autoren
Elsevier eBooks·2019
Pharmakotherapie der Schizophrenie (ICD-10 F2)
Elsevier eBooks·2019
Should antidepressants be used in minor depression?
Dialogues in Clinical Neuroscience·2018· 26 citedOpen Access
Psychiatric sequelae of cardiac arrest
Dialogues in Clinical Neuroscience·2018· 35 citedOpen Access
page 1 of 29Next →

Frequent Co-authors

Martin Lambert(14), Steffen Moritz(11), Anne Karow(9), Anna Wirz‐Justice(6), Benno G. Schimmelmann(5), Marian S. Kafka(5), Rüdiger Holzbach(4), B. Andresen(3), Stefan Leucht(3), Eduard Vieta(3), Alexander Schacht(3), David L. Suarez(3), Josep María Haro(3), Diego Novick(3), Regina Dittmann(3), Markus M. Nöthen(3), Michael Riedel(3), Thomas A. Wehr(3), Falk Kiefer(2), Holger Jahn(2)